KANT (Kineta) 1-Year ROIIC % : -399.56% (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Kineta 1-Year ROIIC %?

1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year. Kineta's 1-Year ROIIC % for the quarter that ended in Jun. 2024 was -399.56%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Kineta's 1-Year ROIIC % or its related term are showing as below:

KANT's 1-Year ROIIC % is ranked worse than
83.26% of 1422 companies
in the Biotechnology industry
Industry Median: -11.235 vs KANT: -399.56

Kineta 1-Year ROIIC % Historical Data

The historical data trend for Kineta's 1-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kineta 1-Year ROIIC % Chart

Kineta Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

1-Year ROIIC %

-563.82

346.40

2,739.70

Kineta Quarterly Data
	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
1-Year ROIIC %	Get a 7-Day Free Trial								867.10	246.13	2,739.70	-782.92	-399.56

Competitive Comparison of Kineta's 1-Year ROIIC %

For the Biotechnology subindustry, Kineta's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kineta's 1-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kineta's 1-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Kineta's 1-Year ROIIC % falls into.

Kineta 1-Year ROIIC % Calculation

Kineta's 1-Year ROIIC % for the quarter that ended in Jun. 2024 is calculated as:

1-Year ROIIC %	=	1-Year Incremental Net Operating Profit After Taxes (NOPAT)^**	/	1-Year Incremental Invested Capital
	=	( -17.251 (Jun. 2024) - -38.927 (Jun. 2023) )	/	( 1.311 (Jun. 2024) - 6.736 (Jun. 2023) )
	=	21.676	/	-5.425
	=	-399.56%^***

** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.

Kineta (OTCPK:KANT) 1-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.

Kineta 1-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Kineta's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.

Kineta Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kineta Inc (OTCPK:KANT) » Definitions » 1-Year ROIIC %

Comparable Companies

Traded in Other Exchanges

J75:Germany

Address

7683 SE 27th Street, Suite 481, Mercer Island, WA, USA, 98040

Website

https://www.kinetabio.com

Kineta Inc is a clinical-stage biotechnology company with a mission to develop next generation immunotherapies that transform patients' lives. The company's asset is KVA12.1, a VISTA blocking immunotherapy.

Executives

Raymond J. Bartoszek	director	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Shawn Iadonato	director, officer: Chief Executive Officer	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Craig W. Philips	officer: President	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Pauline Kenny	officer: General Counsel	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Keith Baker	officer: Chief Financial Officer	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Thierry Guillaudeux	officer: Chief Scientific Officer	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Scott J. Dylla	director	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Marion R Foote	director	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Michael D Wyzga	officer: See Remarks	C/O YUMANITY, INC., 40 GUEST STREET, SUITE 4410, BOSTON MA 02135
Devin Whittemore Smith	officer: SVP and General Counsel	C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Kimberlee C Drapkin	director	PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Ajay Verma	officer: EVP, Head of R&D	C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Lynne Zydowsky	director	C/O YUMANITY THERAPEUTICS, INC., 40 GUEST STREET, BOSTON MA 02135
Susan L. Lindquist Exempt Marital Trust	10 percent owner	C/O NANCY E. DEMPZE, HEMENWAY & BARNES, LLP, 75 STATE STREET, BOSTON MA 02109
Susan L. Lindquist Massachusetts Non-exempt Marital Trust	10 percent owner	C/O NANCY DEMPZE, HEMENWAY & BARNES, LLP, 75 STATE STREET, BOSTON MA 02109